Literature DB >> 12619938

Cytokines, osteoprotegerin, and RANKL in vitro and histomorphometric indices of bone turnover in patients with different bone diseases.

Heide Siggelkow1, Thorsten Eidner, Gabriele Lehmann, Volker Viereck, Dirk Raddatz, Ullrich Munzel, Gert Hein, Michael Hüfner.   

Abstract

Cytokines are supposed to play an essential role in the regulation of the bone metabolic unit. However, information on cytokine production of primary human osteoblasts from patients with metabolic bone disease is scarce, and few attempts have been made to correlate such data to histomorphometric parameters of individual patients. We investigated 11 patients with metabolic bone disease referred to our outpatient department for bone biopsy and analyzed interleukin (IL)-1, IL-6, and TNF-alpha protein release and gene expression in primary osteoblast cultures. Compared with four controls, five patients showed normal cytokine protein release, whereas six patients showed much higher levels of interleukin-6 (26-fold) and TNF-alpha (84-fold). All three cytokines were strongly correlated concerning gene expression and/or protein levels (r = 0.72-0.96). Histomorphometric analysis of the bone samples showed that eroded surface (ES/BS) as a parameter of bone resorption was significantly associated with TNF-a. In addition, RANKL gene expression was positively associated with ES/BS and osteoclast surface (Oc.S/BS). Finally, the formation parameters osteoid volume and osteoid surface were negatively associated with TNF-alpha. In conclusion, in an in vitro-ex vivo model of bone cells obtained from a group of 11 patients with different forms of metabolic bone disease, cytokine release in conditioned medium was significantly associated with bone resorption and bone formation, as quantified by histomorphometry. TNF-alpha seemed to be the more important cytokine; its effect on bone resorption could be mediated by RANKL.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12619938     DOI: 10.1359/jbmr.2003.18.3.529

Source DB:  PubMed          Journal:  J Bone Miner Res        ISSN: 0884-0431            Impact factor:   6.741


  17 in total

1.  Vitamin D, osteoprotegerin/receptor activator of nuclear factor-kappaB ligand (OPG/RANKL) and inflammation with alendronate treatment in HIV-infected patients with reduced bone mineral density.

Authors:  J Natsag; M A Kendall; D E Sellmeyer; G A McComsey; T T Brown
Journal:  HIV Med       Date:  2015-07-16       Impact factor: 3.180

2.  Osteoblast Differentiation and Bone Matrix Formation In Vivo and In Vitro.

Authors:  Harry C Blair; Quitterie C Larrouture; Yanan Li; Hang Lin; Donna Beer-Stoltz; Li Liu; Rocky S Tuan; Lisa J Robinson; Paul H Schlesinger; Deborah J Nelson
Journal:  Tissue Eng Part B Rev       Date:  2016-12-27       Impact factor: 6.389

Review 3.  Accelerated aging and human immunodeficiency virus infection: emerging challenges of growing older in the era of successful antiretroviral therapy.

Authors:  Ramona Bhatia; Patrick Ryscavage; Babafemi Taiwo
Journal:  J Neurovirol       Date:  2011-12-29       Impact factor: 2.643

Review 4.  Nephrolithiasis-associated bone disease: pathogenesis and treatment options.

Authors:  Khashayar Sakhaee; Naim M Maalouf; Rajiv Kumar; Andreas Pasch; Orson W Moe
Journal:  Kidney Int       Date:  2010-12-01       Impact factor: 10.612

5.  Changes in Bone Mineral Density After Initiation of Antiretroviral Treatment With Tenofovir Disoproxil Fumarate/Emtricitabine Plus Atazanavir/Ritonavir, Darunavir/Ritonavir, or Raltegravir.

Authors:  Todd T Brown; Carlee Moser; Judith S Currier; Heather J Ribaudo; Jennifer Rothenberg; Theodoros Kelesidis; Otto Yang; Michael P Dubé; Robert L Murphy; James H Stein; Grace A McComsey
Journal:  J Infect Dis       Date:  2015-05-05       Impact factor: 5.226

6.  Skeletal health of children and adolescents with inflammatory bowel disease.

Authors:  Helen Pappa; Meena Thayu; Francisco Sylvester; Mary Leonard; Babette Zemel; Catherine Gordon
Journal:  J Pediatr Gastroenterol Nutr       Date:  2011-07       Impact factor: 2.839

7.  Less Bone Loss With Maraviroc- Versus Tenofovir-Containing Antiretroviral Therapy in the AIDS Clinical Trials Group A5303 Study.

Authors:  Babafemi O Taiwo; Ellen S Chan; Carl J Fichtenbaum; Heather Ribaudo; Athe Tsibris; Karin L Klingman; Joseph J Eron; Baiba Berzins; Kevin Robertson; Alan Landay; Igho Ofotokun; Todd Brown
Journal:  Clin Infect Dis       Date:  2015-06-09       Impact factor: 9.079

8.  Negative effects of nicotine on bone-resorbing cytokines and bone histomorphometric parameters in male rats.

Authors:  Hermizi Hapidin; Faizah Othman; Ima-Nirwana Soelaiman; Ahmad N Shuid; Douglas A Luke; Norazlina Mohamed
Journal:  J Bone Miner Metab       Date:  2007-02-26       Impact factor: 2.626

9.  RANKL is a mediator of bone resorption in idiopathic hypercalciuria.

Authors:  Samirah Abreu Gomes; Luciene Machado dos Reis; Irene Lourdes Noronha; Vanda Jorgetti; Ita Pfeferman Heilberg
Journal:  Clin J Am Soc Nephrol       Date:  2008-05-14       Impact factor: 8.237

10.  Differentiation dependent expression of urocortin's mRNA and peptide in human osteoprogenitor cells: influence of BMP-2, TGF-beta-1 and dexamethasone.

Authors:  Mohammad Tezval; Hossein Tezval; Klaus Dresing; Ewa Klara Stuermer; Martina Blaschke; Klaus Michael Stuermer; Heide Siggelkow
Journal:  J Mol Histol       Date:  2009-12-01       Impact factor: 2.611

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.